

21 March 2025

ASX Release

Notice under Section 708A of the Corporations Act

This notice is given by **Firebrick Pharma Limited** (**Issuer** or **Company**) (**ASX:FRE**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) ("**Act**").

The Company has today issued 2,700,000 ordinary fully paid shares upon the exercise of unlisted options at an exercise price of \$0.01 per ordinary fully paid share ("**Issued Shares**").

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Issued Shares were issued without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and sections 674 and 674A of the Act; and
3. as at the date of this notice there is no information that is 'excluded' information within the meanings of section 708A(7) and 708A(8) of the Act, being information:
 - a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
 - b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - ii. the rights and liabilities attaching to the Securities.

This announcement has been authorised for release by the Board of Firebrick Pharma Limited.

Yours faithfully



Stephen Buckley

Company Secretary

**About Firebrick (ASX:FRE)**

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick recently introduced Nasodine in the United States, Singapore and Fiji and South Pacific, with an agreement in place to also launch Nasodine in the Philippines.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com